Janssen Looks To Differentiate Anticoagulant Xarelto With Broad Label
Executive Summary
With positive data now in for Xarelto’s ability to treat and prevention recurrence of VTE, Janssen looks to file for a fourth indication for the novel anticoagulant, positioning the drug to crack a promising market that may be under-appreciated.
You may also be interested in...
COMPASS Success Reinforces J&J/Bayer's Broad Labeling Strategy For Xarelto
J&J will be talking to FDA regarding expanded approval for peripheral arterial disease and coronary artery disease following early stop of COMPASS outcomes study; strong data will be needed if asymptomatic patients are targeted.
Xarelto Indication Expansion Efforts Show That Fewer Could Be More
J&J and Bayer continue quest for acute coronary syndrome claim following three rejections by FDA; this time, Xarelto will be tested on top of only one antiplatelet drug instead of two.
Xarelto Falters Again In ACS Bid, As Competitors Aim To Catch Up To J&J Drug’s Label
FDA’s third rejection of J&J’s attempt to expand use of Xarelto to ACS patients comes as competing oral anticoagulants await agency action on pending applications that could match Xarelto’s breadth of approved indications.